Login / Signup

Treatment with Elapegademase Restores Immunity in Infants with Adenosine Deaminase Deficient Severe Combined Immunodeficiency.

Elizabeth Daly HicksGeoffrey HallMichael S HershfieldTeresa K TarrantPawan BaliJohn W SleasmanRebecca H BuckleyTalal Mousallem
Published in: Journal of clinical immunology (2024)
Revcovi was safe and effective as initial therapy to restore immune function in these newly diagnosed infants with ADA-SCID, however, time course and degree of reconstitution varied. Revcovi dose may need to be optimized based on immune reconstitution, clinical status, and biochemical data.
Keyphrases
  • newly diagnosed
  • electronic health record
  • early onset
  • big data
  • stem cells
  • machine learning
  • protein kinase
  • deep learning
  • smoking cessation